Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00502892 · ClinicalTrials.gov registry record · Phase 1

Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
2
Enrollment target
1
Study location

NCT00502892 is a Phase 1 study of Solid Tumors that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants, below the 285-participant average among 125 other Solid Tumors trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00502892, a Phase 1 study of Solid Tumors, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
2 participants
Enrollment target
1
Study location

Study Summary

Primary Objectives: * To determine the maximum tolerated dose (MTD) of Topotecan when added to a fixed dose regimen of Ifosfamide and Carboplatin in children and young adults with solid tumors. * To evaluate the toxicity associated with the administration of Topotecan with Ifosfamide and Carboplatin (TIC) in children and young adults with solid tumors. Secondary Objectives: * To evaluate the duration of neutropenia (ANC\<500/micro L) and thrombocytopenia (PLT 50,000/ micro L and 20,000/ micro L) and the number of days of platelet transfusion during each course of TIC chemotherapy when used in conjunction with G-CSF and NEUMEGA in children and young adults with solid tumors. * To determine the median number of apheresis collections as well as the CD34/kg, CD41/kg, CD61/kg and CD34:41/kg and CD34:61/kg per collection in patients electively undergoing concurrent apheresis for peripheral blood stem cell collection in courses 2 or 3. * To determine the median number of peripheral blood mononuclear cells (PBMC) and ex-vivo expanded myeloid dendritic cells (DC) in patients electively undergoing concurrent apheresis for PBMC collection in courses 2 or 3.

Conditions Studied

Solid Tumors

Interventions

  • DRUG Carboplatin
  • DRUG Ifosfamide
  • DRUG Topotecan

Study Locations (1)

Texas

  • U.T.M.D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2004-08
Est. Completion 2010-01
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00502892

The ClinicalTrials.gov registry entry for NCT00502892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 125 other Solid Tumors trials with a reported enrollment target (99% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.

NCT00502892 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00502892 about?

NCT00502892 is a clinical study titled "Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors". Primary Objectives: * To determine the maximum tolerated dose (MTD) of Topotecan when added to a fixed dose regimen of Ifosfamide and Carboplatin in children and young adults with solid tumors. * To evaluate the toxicity associated with the administration of Topotecan with Ifosfamide and Carboplati...

What is the current status of trial NCT00502892?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2004-08. Estimated completion is 2010-01.

What conditions does trial NCT00502892 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT00502892?

The interventions under investigation include: Carboplatin (DRUG), Ifosfamide (DRUG), Topotecan (DRUG).

Who is sponsoring clinical trial NCT00502892?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00502892 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.